Caring for People with Dementia: a clinical practice guideline for the radiography workforce

Caring for People with Dementia: a clinical practice guideline for the radiography
workforce (imaging and radiotherapy) | The Society and College of Radiographers

Caring for people with Dementia: a clinical practice guideline for the radiography workforce (imaging and radiotherapy) is a comprehensive and evidence-based document. It has a set of recommendations for the whole radiographic workforce caring for people with dementia and carers when undergoing imaging and/or radiotherapy. It has been developed systematically using the best available evidence from research and expert opinion, including service users, and subjected to peer professional, lay and external review.

scor
Image source: http://www.sor.org

The guideline has recommendations for good practice for individual members of the radiographic workforce, service managers, academic institutions and the Society and College of Radiographers (SCoR).

As a whole, this guideline acts to highlight to practitioners that to offer the best service and healthcare outcomes for people with dementia and carers, care must be tailored to the needs of the invidual.

There have been minor changes to the language used in this second edition, which emphasises the ability of and need for people with dementia to continue to live well with a good quality of meaningful life.

Full document: Caring for People with Dementia: a clinical practice guideline for the radiography workforce

NICE Guideline: COVID-19 rapid guideline: delivery of systemic anticancer treatments

NICE | March  2020 |COVID-19 rapid guideline: delivery of systemic anticancer treatments

NICE guideline [NG161]

The purpose of this guideline is to maximise the safety of patients with cancer and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match the capacity for cancer treatment to patient needs if services become limited because of the COVID-19 pandemic.

On 3 April 2020, NICE added 2 recommendations on when to offer and continue systemic anticancer treatment for patients with COVID-19. NICE also amended the table on prioritising treatments in line with new advice from NHS England.

 

This guideline is for:

  • health and care practitioners
  • health and care staff involved in planning and delivering services
  • commissioners

Further information availlable from NICE 

NICE has also produced a COVID-19 rapid guideline on delivery of radiotherapy.

COVID-19 rapid guideline: delivery of radiotherapy

NICE | March 2020| COVID-19 rapid guideline: delivery of radiotherapy

The purpose of this guideline is to maximise the safety of patients who need radiotherapy and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match the capacity for radiotherapy to patient needs if services become limited because of the COVID-19 pandemic.

NICE has also produced a COVID-19 rapid guideline on delivery of systemic anticancer treatments.

This guideline is for:

  • health and care practitioners
  • health and care staff involved in planning and delivering services
  • commissioners

Full details from NICE

Colorectal cancer

Colorectal cancer | NICE guideline [NG151] | January 2020

This guideline covers managing colorectal (bowel) cancer in people aged 18 and over. It aims to improve quality of life and survival for adults with colorectal cancer through management of local disease and management of secondary tumours (metastatic disease).

Recommendations

This guideline includes recommendations on:

See also: Colorectal cancer (Quality Standard 20, updated from Aug 2012)

[NICE Guideline] Prostate cancer: diagnosis and management [NG131]

NICE |  May 2019 | Prostate cancer: diagnosis and management NICE guideline [NG131]

This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.

Full details from NICE 

Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years Technology appraisal guidance [TA554]

NICE | December 2018 | Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years | Technology appraisal guidance [TA554]

 

Evidence-based recommendations on tisagenlecleucel therapy (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years.

 

Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years

 

See also: NICE recommends another revolutionary CAR T-cell therapy for adults with lymphoma

Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer Technology appraisal guidance [TA555]

NICE | January 2019 |Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer Technology appraisal guidance [TA555]

 

Evidence-based recommendations on regorafenib (Stivarga) for treating advanced hepatocellular carcinoma in adults who have had sorafenib.

Full details from NICE